Eli Lilly’s so-called triple-G reduced blood sugar levels in patients with type 2 diabetes by up to 1.9% in a late-stage trial — a slightly lower margin than Mounjaro achieved in its pivotal diabetes study.
The …
Washington’s Medicaid program will start paying for a friendly AI-powered robot called ElliQ to keep seniors company and help them stay independent and healthy at
GSK’s recent deal to license out a rare liver disease drug just got sweeter. The FDA on Thursday approved linerixibat to treat cholestatic itch in
As geopolitical tensions ratchet up around the world, an initiative has been launched to drive improvements in diagnostic accuracy and precision care.
Novo Nordisk is facing generic semaglutide in India, Atrogi is testing a new weight loss approach, and Structure has more data with its oral GLP-1.
After selling her previous biotech for over $1 billion in 2019, it didn’t take long before Clarissa Desjardins decided to try it again. Desjardins founded
Eli Lilly’s so-called triple-G reduced blood sugar levels in patients with type 2 diabetes by up to 1.9% in a late-stage trial — a slightly lower margin than Mounjaro achieved in its pivotal diabetes study.
The …